Racial Variation in Prostate Cancer Care Explored

Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

In the United States, racial variations have been documented in the incidence, mortality, and clinical management of cancers of the breast, colon, lung, and prostate.[1-4] In conjunction with similar findings from nonmalignant diseases, such as cardiovascular and cerebrovascular disease, these data suggest that racial variations in medical care are widespread.[5-8] However, few empirical studies explain why these racial variations exist at all.

In the United States, racial variations have been documented in theincidence, mortality, and clinical management of cancers of the breast,colon, lung, and prostate.[1-4] In conjunction with similar findings fromnonmalignant diseases, such as cardiovascular and cerebrovascular disease,these data suggest that racial variations in medical care are widespread.[5-8]However, few empirical studies explain why these racial variations existat all.

There are several potential explanations for these findings. First isa consideration of racial discrimination in medical care.[9] Second, differencesin socioeconomic status and income, rather than race, might be importantfactors. For example, racial differences in incidence and survival forsome cancers have been linked to socioeconomic status.[10-12] Socioeconomicstatus may also account for variations in patterns of care.

Third, clinical factors may differ according to race/ethnicity, includingdisease pathophysiology, stage at presentation, or comorbid conditionsthat may be contraindications to some therapies or otherwise modify thechoice of treatment. Fourth, there may be racial or cultural differencesin patient preferences for care.

Understanding the extent of, and factors associated with, racial variationsin the care of men with prostate cancer is especially important. Recentadvances in prostate cancer screening have resulted in higher rates ofearly-stage disease among whites more so than blacks.

The Concept of Race

Race is regarded as a social concept that reflects historical socialand economic events and not as a biological entity.[13-15] Indeed, somehealth researchers contend that race has no biological meaning and shouldbe abandoned as a variable in analyses, particularly because the concepthas been used in the past to bolster racist arguments of the purportedinherent superiority of some racial groups.[16,17]

The socioeconomic aspects of race have been evaluated previously, whilepotential biological aspects have been virtually ignored.[18,19] Althoughrace is intimately intertwined with socioeconomic status (at least in theUS), the two terms reflect different concepts.[20,21]

For example, race may also be an indicator of genetic proclivities forcancer development, a proxy for economic factors, eg, ability to pay forcare, or a marker for cultural orientation, eg, patient preferences forcertain therapies or misunderstandings about some therapies.

The policy implications of these alternative explanations are widelydifferent, varying from educational strategies, health care financing reform,or program targeting to high-risk populations.

Among males, prostate cancer is second only to lung cancer in incidenceand mortality, with significant racial differences in both factors.[1]In 1992, the age-adjusted incidence rate for prostate cancer was 187.6per 100,000 for blacks vs 139.4 per 100,000 for whites, yielding an overallrate ratio of 1.3.

The age-adjusted mortality rate for prostate cancer for 1988 to 1992was 53.5 per 100,000 for blacks vs 24.0 per 100,000 for whites, a mortalityrate ratio of 2.2. This is one of the largest ratios for site-specificcancer mortality.

Blacks consistently present at a later stage of prostate cancer. However,adjusting for stage at presentation does not eliminate the racial disparitiesin survival rates; rather, the survival gap between blacks and whites demonstratesa broadening with advanced stage.

Patterns of Care

Racial/ethnic differences are apparent in the care of prostate cancerpatients. For example, black patients are substantially more likely thanwhites to receive hormonal therapy alone but are less likely to undergoprostatectomy alone. This pattern appears to persist over time.

There is a relatively extensive and consistent literature regardingthe role of clinical and socioeconomic factors in explaining racial differencesin types of prostate cancer therapy, but no literature on the importanceof either patient preferences or the patient-physician interaction.

It is not known if differences in care contribute to the lower survivalrates among blacks. Some studies have reported that when treatments aresimilar between blacks and whites, outcomes are similar. Among patientson standard oncology protocols, there is uniformity in evaluation and treatment,as well as overall survival and disease-free survival.[22] Similarly, inequal access systems, no significant racial difference in overall survivalis reported.[23,24]

However, the literature linking specific treatments with outcomes accordingto race does not consistently indicate these findings. In one study, timeto recurrence was shorter among the black vis-à-vis the white patientswho underwent a radical prostatectomy.[25]

Stage at Presentation

Studies suggest that stage at presentation is a primary explanationof the racial difference in therapy. Among patients in the Virginia CancerRegistry who have local or regional disease, blacks are more likely thanwhites to receive either no treatment or hormonal therapy but less likelyto receive either surgery or radiation.[26] With adjustment for socioeconomic,clinical, and health care system characteristics, there is no racial differencein either the likelihood of receiving any treatment versus no treatmentor in receiving hormonal therapy or orchiec-tomy versus surgery or radiation.

However, SEER data indicate that, among localized disease patients,blacks are only two thirds as likely to receive radical prostatectomy orradiation.[27]

Ability to Pay

Given the general importance of ability to pay for care in gaining accessto health care, it is reasonable to expect that socioeconomic status isan important determinant of therapy. However, review of the evidence fromfederal and non-federal patterns of care studies suggest that ability topay may have little or no role in explaining racial variations in the typesof therapy for prostate cancer.

Within the health care systems of the Veterans Health Administrationor Department of Defense medical centers, financial incentives for providingor withholding care are minimal. However, one patterns of care study foundracial variations in care similar to those seen in the nonfederal healthcare sector.[23]

Moreover, even in studies that control for socioeconomic status, racialdifferences in type of therapy persist.[26] In addition, clinical factorssuch as comor-bid conditions may account for some of the variation in care.[26]

Finally, ability to pay is just one dimension of socioeconomic status.Other dimensions of socioeconomic status, such as education or knowledge,may be worth exploring as possible additional factors that have a rolein explaining the racial differences in prostate cancer therapy.

Variations in Patient Preferences

Neither racial variations in patient preferences, knowledge, and beliefsnor the role of the patient's race in the patient-physician decision-makingprocess has been thoroughly investigated as a potential explanation ofthe observed racial differences in patterns of care.

Recent investigations suggest that blacks are less likely to see themselvesas being at high risk of prostate cancer and may have a more pessimisticview of the impact of prostate cancer on quality of life and of the prognosis.[28-30]Such attitudes may indirectly account for the racial differences in thetherapies used by influencing when in the natural history of this diseaseblack patients present.

Future Research

Given that racial variation in the clinical stage at presentation primarilyexplains the observed differences in use of therapies, there are at leasttwo compelling avenues for future investigations of racial differencesin the treatment of prostate cancer.

One is racial differences in disease pathophysiology and their implicationsfor screening and early detection programs. Blacks may experience a moreaggressive form of prostate cancer.[31] There is a long history of epidemiologicalstudies that document a higher incidence and earlier onset of prostatecancer among blacks.[32-36]

Also, time to recurrence may be shorter in black than in white prostatecancer patients, despite similar treatment and similar clinical stage atpresentation.[22,25] Finally, latent prostate cancers are greater in volumeamong blacks than whites.[37,38]

Even if a more aggressive form of prostate cancer does not afflict blacks,studies show consistently that blacks present at a later clinical stageof disease than whites even in equal access systems such as the VeteransHealth Administration and Department of Defense.[23,39,40]

Existing evidence, which is far from sufficient, indicates that blacksdo not perceive themselves to be at high risk for prostate cancer, whilethe epidemiology of prostate cancer clearly indicates that they are athigh risk. Moreover, blacks may be delaying evaluation because of fearsregarding disease prognosis.[28,30]

Prostate cancer is one of several cancers that affect US racial andethnic groups differently, with blacks experiencing a higher incidenceand mortality rate than whites. Black patients with prostate cancer areless likely to receive definitive therapy. This pattern of care differenceappears to be attributable primarily to the later clinical stage of diseaseat presentation; socioeconomic considerations, which relate to access tocare, appear to play a lesser role.

Other patient-related factors, for example, preferences for certaintherapies, have not been well studied; consequently, their ability to explainracial variations in treatment is unclear.

Potential areas for future research should focus on the reasons forthe detection of the disease at a later clinical stage and, hence, itsworse prognosis.


1. Wingo PA, Bolden S, Tong T, et al: Cancer statistics for AfricanAmericans. CA-A Cancer J Clin 46:113-125, 1996.

2. Ries LAG, Miller BA, Hankey BF, et al (eds): SEER Cancer StatisticsReview, 1973-91. NIH Pub. 94-2789. Bethesda, Md, National Cancer Institute,1994.

3. Cooper GS, Yuan Z, Landefeld CS, et al: Surgery for colorectal cancer:Race-related differences in rates and survival among Medicare beneficiaries.Am J Public Health 86:582-586, 1996.

4. Mettlin CJ, Murphy G: The National Cancer Data Base report on prostatecancer. Cancer 74:1640-1648, 1994.

5. Horner RD, Matchar DB, Divine GW, et al: Racial variation in ischemicstroke-related physical and functional impairments. Stroke 22:1497-1501,1991.

6. Whittle J, Conigliaro J, Good CB, et al: Racial differences in theuse of invasive cardiovascular procedures in the Department of VeteransAffairs medical system. N Engl J Med 329:621-627, 1993.

7. Oddone EZ, Horner RD, Monger ME, et al: Racial variation in the ratesof carotid angiography and endarterectomy in patients with stroke and transientischemic attack. Arch Intern Med 153:2781-2786, 1993.

8. Horner RD, Oddone EZ, Matchar DB: Theories explaining racial differencesin the utilization of diagnostic and therapeutic procedures for cerebrovasculardisease. Milbank Q 73:443-462, 1995.

9. Geiger HJ: Race and health care--an American dilemma? N Engl J Med335:815-816, 1996.

10. McWhorter WP et al: Contribution of socioeconomic status to black/whitedifferences in cancer incidence. Cancer 63:982-987, 1989.

11. Gorey KM, Vena JE: Cancer differentials among US blacks and whites:Quantitative estimates of socioeconomic-related risks. J Natl Med Asso86:209-215, 1994.

12. Cella DF et al: Socioeconomic status and cancer survival. J ClinOncol 9:1500-1509, 1991.

13. Watts ES: The biological race concept and diseases of modern man,in Rothschild HR (ed): Biocultural Aspects of Disease, pp 3-23. New York,Academic Press, Inc, 1981.

14. Cooper R, David R: The biological concept of race and the applicationto public health and epidemiology. J Health Polit Policy Law 11:97-116,1986.

15. Witzig R: The medicalization of race: Scientific legitimizationof a flawed social construct. Ann Intern Med 125:675-679, 1996.

16. Osborne NG, Feit MD: The use of race in medical research. JAMA 267:275-279,1992.

17. Schulman KA et al: The roles of race and socioeconomic factors inhealth services research. Health Serv Res 30:179-195, 1995.

18. Williams DR: The concept of race in Health Services Research: 1966-1990.Health Serv Res 29:261-274, 1994.

19. Jones CP, LaVeist TA, Lillie-Blanton M: "Race" in theepidemiologic literature: An examination of the American Journal of Epidemiology,1921-1990. Am J Epidemiol 134:1079-1084, 1991.

20. Nickens HW: The role of race/ethnicity and social class in minorityhealth status. Health Serv Res 30:151-162, 1995.

21. Lillie-Blanton M et al: Racial differences in health: Not just blackand white but shades of gray. Ann Rev Public Health 17:411-448, 1996.

22. Roach M et al: The prognostic significance of race and survivalfrom prostate cancer based on patients irradiated on Radiation TherapyOncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys 24:441-449,1992.

23. Optenberg SA et al: Race, treatment, and long-term survival fromprostate cancer in an equal-access medical care delivery system. JAMA 274:1599-1605,1995.

24. Fowler JE, Terrell F: Survival in blacks and whites after treatmentfor localized prostate cancer. J Urol 156:133-136, 1996.

25. Moul JW et al: Black race is an adverse prognostic factor for prostatecancer recurrence following radical prostatectomy in an equal access healthcare setting. J Urol 155:1667-1673, 1996.

26. Desch CE et al: Factors that determine the treatment for local andregional prostate cancer. Med Care 34:152-162, 1996.

27. Schapira MM, McAuliffe TL, Nattinger AB: Treatment of localizedprostate cancer in African-American compared with Caucasian men: Less useof aggressive therapy for comparable disease. Med Care 33:1079-1088, 1995.

28. Demark-Wahnefried W et al: Knowledge, beliefs, and prior screeningbehavior among blacks and whites reporting for prostate cancer screening.Urology 46:346-351, 1995.

29. Price JH, Colvin TL, Smith D: Prostate cancer: Perceptions of African-Americanmales. J Natl Med Asso 85:941-947, 1993.

30. Price JH et al: Black American's perceptions of cancer: A studyutilizing the Health Belief Model. J Natl Med Asso 80:1297-1304, 1988.

31. Morton RA: Racial differences in adenocar-cinoma of the prostatein North American men. Urology 44:637-645, 1994.

32. Whitmore WF: Localized prostatic cancer: Management and detectionissues. Lancet 334:1263-1267, 1994.

33. Nomura AMY, Kolonel LN: Prostate cancer: A current perspective.Epidemiol Rev 13:200-227, 1991.

34. Dayal HH, Polissar L, Dahlberg S: Race, socioeconomic status, andprostatic cancer. J Natl Cancer Inst 74:1001-1006, 1985.

35. Dayal HH, Chiu C: Factors associated with racial differences insurvival for prostatic carcinoma. J Chronic Dis 35:553-560, 1982.

36. Ernster VL et al: Prostatic cancer: Mortality and incidence ratesby race and social class. Am J Epidemiol 107:311-320, 1978.

37. Whittemore AS, Keller JB, Betensky R: Low-grade, latent prostatecancer volume: Predictor of clinical cancer incidence? J Natl Cancer Inst83:1231-1235, 1991.

38. Guileyardo JM et al: Prevalence of latent prostate carcinoma intwo U.S. populations. J Natl Cancer Inst 65:311-316, 1980.

39. Powell IJ, Schwartz K, Hussain M: Removal of the financial barrierto health care: Does it impact on prostate cancer at presentation and survival?A comparative study between black and white men in a Veterans Affairs system.Urology 46:825-830, 1995.

40. Brawn PN et al: Stage of presentation and survival of white andblack patients with prostate carcinoma. Cancer 70:2569-2573, 1993.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content